Clinical Trial Update: TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant [Phase 2]

View source ↗

Summary

Completed Phase 2 trial of TAMOVALCIR in allogeneic hematopoietic progenitor transplant to address cytomegalovirus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• TAMOVALCIR

Snippet

Sponsor: PETHEMA Foundation | Conditions: Cytomegalovirus Infection | Phase 2 | Status: COMPLETED